Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Nadia Harbeck(Breast Center), Marion van Mackelenbergh(University Hospital Schleswig-Holstein), Roisín M. Connolly(Johns Hopkins University), Amelia McCartney(St John of God Subiaco Hospital), Nicole McCarthy(Monash Medical Centre), Maja V. Maraldo(University of Copenhagen), Frederik Marmé(Heidelberg University), Belinda Yeo(Austin Health), Naoki Niikura(Tokai University), Peter A. Fasching(Universitätsklinikum Erlangen), Nana Scotto(AstraZeneca (Switzerland)), Joëlle Collignon(Centre Hospitalier Universitaire de Liège), Eveline Cuypere(Sunnybrook Health Science Centre), Manoj Prahladan(AstraZeneca (United Kingdom)), Timothy Clay(Duke Medical Center), Michaela J. Higgins(Cancer Trials Ireland), María Gión(Hospital Universitario Ramón y Cajal), Minna Tanner(Tampere University Hospital), Valentina Guarneri(Istituto Oncologico Veneto), Rupert Bartsch(Universitätszahnklinik Wien), Nancy U. Lin(Dana-Farber Cancer Institute), Pauline Wimberger(University Hospital Carl Gustav Carus), Giampaolo Bianchini(Vita-Salute San Raffaele University), Hans Wildiers(KU Leuven), Michael Braun(Peter MacCallum Cancer Centre), Mattea Reinisch(University of Mannheim), Johanna Mattson(University of Helsinki), Katarzyna J. Jerzak(Sunnybrook Health Science Centre), Riikka Huovinen(Turku University Hospital), Nataliya Kuptsova‐Clarkson, Nicholas Murray(James Cook University), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Hans Tesch, Tjoung‐Won Park‐Simon(Medizinische Hochschule Hannover), Santiago Escrivá-de-Romaní(Unknown), Eva Ciruelos(Hospital Universitario 12 De Octubre), Stephen Chia(BC Cancer Agency), Giuseppe Viale(University of Milan), Eva Brix(Gentofte Hospital), Jeanette Dupont Rønlev(Odense University Hospital), Andrea Gombos, Sunil Verma(VA Boston Healthcare System), Eva Maria Grischke(Heidelberg University), Christian Kurzeder(Breast Center), Volkmar Müller(Universität Hamburg), Helen Bridge(AstraZeneca (United Kingdom)), Sally Baron‐Hay(Royal North Shore Hospital), Joke Tio(Ludwig-Maximilians-Universität München), Michael Untch(Helios Kliniken)
Cited by 8
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k